Drug intelligence / Profile preview

KFP-H013

Development stage: Preclinical
Lead developer: Carephar
Modality: Small Molecules

Overview

KFP-H013 is an investigational small molecule oncology therapeutic being developed by Nanjing Carephar Pharmaceutical. According to company pipeline information, the program reached the IND-enabling stage around 2021, with filings planned for both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA). While the specific mechanism of action and target indications within oncology remain proprietary, the drug represents part of Carephar's expanding R&D portfolio in the cancer space.

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on KFP-H013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFP-H013.

Explore the full profile